May 12
Current report
8-K
Regulation FD disclosure
KROS · Keros Therapeutics, Inc. · Documents
$10.08
+0.54 (+5.66%)
At close · Nov 12
Return incl. dividend (before tax)
Market Cap
$197.81M
Shares
19.62M
Volume · Nov 12
630.16K
Avg daily vol (3M)
187.94K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2025
May 9
Proxy statement
DEFA14A
Proxy statement
May 6
Current report
8-K
Financial results
May 6
Quarterly report
10-Q
FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $211.19M
Net income $148.45M
Diluted EPS $3.62
Apr 23
Proxy statement
DEF 14A
Meeting Jun 4, 2025
Proxy statement
Apr 23
Annual report to holders
ARS
Annual report to holders
Apr 23
Proxy statement
DEFA14A
Proxy statement
Apr 18
Current report
8-K
Events of Apr 17
Entered into a material agreement
Apr 10
Current report
8-K
Events of Apr 9
Entered into a material agreement, Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events
Mar 31
Current report
8-K
Other events
Mar 6
Current report
8-K
Events of Mar 5
Charter or bylaw amendment, or fiscal year change
Feb 28
Current report
8-K
Regulation FD disclosure
Feb 26
Current report
8-K
Financial results
Feb 26
Annual report
10-K
FY2024, ended Dec 31
Annual report for FY2024
Revenue $3.55M
▲ 2251.0%
Net loss $187.35M
Diluted EPS -$5.00
Jan 30
Current report
8-K
Regulation FD disclosure
Jan 21
Current report
8-K
Events of Jan 16
Other events
Jan 15
Current report
8-K
Other events
Jan 10
Current report
8-K
Regulation FD disclosure
2024
Dec 12
Current report
8-K
Other events
Dec 10
Current report
8-K
Events of Dec 9
Other events
Dec 3
Current report
8-K
Entered into a material agreement, Other events
Nov 26
Current report
8-K
Regulation FD disclosure
Nov 6
Current report
8-K
Regulation FD disclosure
Nov 6
Current report
8-K
Financial results
Nov 6
Quarterly report
10-Q
FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $388K
▲ 4750.0%
Net loss $52.96M
Diluted EPS -$1.41
Oct 16
Current report
8-K
Events of Oct 15
Director or officer change, or executive pay, Other events
Sep 30
Current report
8-K
Other events
Sep 3
Current report
8-K
Other events
Aug 28
Current report
8-K
Regulation FD disclosure
Aug 7
Current report
8-K
Financial results
Aug 7
Current report
8-K
Regulation FD disclosure
Aug 7
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Revenue $37K
Net loss $45.26M
Diluted EPS -$1.25
Jun 17
Current report
8-K
Other events
Jun 17
Current report
8-K
Events of Jun 14
Director or officer change, or executive pay, Other events
Jun 17
Current report
8-K
Other events
Jun 4
Current report
8-K
Other events
Jun 3
Current report
8-K
Regulation FD disclosure
May 30
Current report
8-K
Shareholder vote results
May 28
Current report
8-K
Events of May 23
Director or officer change, or executive pay
May 8
Current report
8-K
Financial results
May 8
Quarterly report
10-Q
FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Revenue $83K
Net loss $43.11M
Diluted EPS -$1.21
May 3
Registration statement
S-3ASR
Registration statement
Apr 17
Proxy statement
DEF 14A
Meeting May 30, 2024
Proxy statement
Apr 17
Annual report to holders
ARS
Annual report to holders
Apr 17
Proxy statement
DEFA14A
Proxy statement
Mar 14
Current report
8-K
Other events
Mar 6
Current report
8-K
Regulation FD disclosure
Mar 5
Current report
8-K
Events of Feb 29
Director or officer change, or executive pay
Mar 5
Current report
8-K
Regulation FD disclosure
Feb 28
Current report
8-K
Financial results
Showing 51–100 of 216 documents
Key facts
CIK
1664710
CUSIP
492327101
13F (30d)
85 filings
70 filers
Visit website
Investor relations